Here we go, another doof. Instead of researching websites and getting answers to questions about late filings etc., their lazy stupid asses would rather read message boards for answers.
Nice observation. It has been this way ever since he arrived and hired his cousin/partner LizzyJefferie to chime in to really dumb down things. These guys are way overpaid. Time for Pig Pharma to review their contract.
Where is that 10K? We have heard this same crap for years even when the PR is staring right in the face. These (your pronoun of choice) agonist keep head banging to no avail... why, because of leronlimab's mechanism of action.
"....due to its selectivity and target-specific mechanism of action, it does not appear to activate the immune function of the CCR5 receptor through agonist activity. This apparent target specificity differentiates leronlimab from other CCR5 antagonists. Leronlimab is a competitive rather than allosteric inhibitor of the CCR5 receptor. Other potential advantages of leronlimab are believed to include longer half-life and less frequent dosing requirements compared to current standard of care daily regimens."
Keep on head bangers. Leronlimab has got ya covered.
News 
Market Data 
Discover 
